|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM340926708 |
| 003 |
DE-627 |
| 005 |
20231226010606.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2022 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2022.109039
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1136.xml
|
| 035 |
|
|
|a (DE-627)NLM340926708
|
| 035 |
|
|
|a (NLM)35569781
|
| 035 |
|
|
|a (PII)S1521-6616(22)00120-6
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Gavrilova, N
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Intravenouse immunoglobuline in dysautonomia
|
| 264 |
|
1 |
|c 2022
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 14.06.2022
|
| 500 |
|
|
|a Date Revised 24.07.2022
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2022 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a Nowadays intravenous immunoglobulin (IVIg) treatment is considered to play a promising role in the autoimmune disease therapy. Despite its significant beneficial effects, the precise mechanism of action needs further studies, as well as recommended dosage in the treatment of autoimmune dysautonomia. In some diseases, like Guillain-Barre syndrome (GBS) and chronic inflammatory demyelinating neuropathy (CIDP), IVIg has a strong evidence that allows to recommend and prescribe the medication, while in other diseases only single case studies are available that requires further research. The review summarizes the currently available information on the effectiveness of IVIg in primary autoimmune neuropathies and neurological complications of systemic diseases, as well as side effects, features of clinical use with an emphasis on doses and treatment protocols in dysautonomia. Being safe and effective therapy, immunologic treatment is one of the most promising tools to achieve clinical remission of dysautonomia and good quality of life in autoimmune patients
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Review
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Autoimmune autonomic gangliopathy (AAG)
|
| 650 |
|
4 |
|a Chronic inflammatory demyelinating neuropathy (CIDP)
|
| 650 |
|
4 |
|a Guillain-Barre syndrome (GBS)
|
| 650 |
|
4 |
|a Intravenous immunoglobulins
|
| 650 |
|
4 |
|a Neuropathy
|
| 650 |
|
4 |
|a Small fiber neuropathy
|
| 650 |
|
7 |
|a Immunoglobulins, Intravenous
|2 NLM
|
| 700 |
1 |
|
|a Kamaeva, E
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ignatova, M
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ryabkova, V
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lukashenko, M
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Soprun, L
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Churilov, L P
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Shoenfeld, Y
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 240(2022) vom: 05. Juli, Seite 109039
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:240
|g year:2022
|g day:05
|g month:07
|g pages:109039
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2022.109039
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 240
|j 2022
|b 05
|c 07
|h 109039
|